MONKEYPOX

This study tested a new RNA-based vaccine (BNT166a) to prevent mpox (formerly monkeypox). It involved 96 healthy adults and looked at safety and how well the vaccine triggers the immune system. The trial was completed and helps determine if the vaccine is safe enough for further …

This study tested whether giving smaller doses of the MVA-BN monkeypox vaccine under the skin (instead of the usual larger dose under the fat) still triggers a strong immune response. About 229 healthy adults aged 18 to 50 received either the standard shot or one of two reduced d…

This study tested the MVA-BN mpox vaccine in about 315 healthy teens aged 12-17 and compared their immune response to about 211 adults. The goal was to see if the vaccine works as well in teens as it does in adults. Researchers also closely monitored safety, including any side ef…

This study checked how safe the MVA-BN (Jynneos) vaccine is for adults at high risk of monkeypox. About 500 staff and study workers in the Democratic Republic of the Congo received two vaccine doses. Researchers tracked any side effects or serious health problems for up to 28 day…

This study tested whether the drug tecovirimat is safe and effective for treating monkeypox (mpox) in adults and children. About 600 participants received either tecovirimat or a placebo, along with standard care, for 14 days. The main goal was to see how quickly skin lesions hea…

This study looked at 320 people in the Democratic Republic of Congo who had mpox (monkeypox) to see how often the virus causes eye problems. Researchers performed standard eye exams to check for issues like vision loss, eye surface damage, or nerve problems. The goal was to bette…